Lipidosome encapsulated ruthenium polypyridine complex and application thereof

A ruthenium polypyridine and liposome technology, which is applied in the field of liposome-encapsulated ruthenium polypyridine complexes, can solve the problems of strong toxicity and physical damage of cancer patients, and achieve low toxicity, low side effects and good therapeutic effect Effect

Active Publication Date: 2018-11-06
WENZHOU INST OF BIOMATERIALS & ENG
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, cisplatin has strong side effects, including nephrotoxicity, myelosuppression, neurotoxicity, gastrointestinal toxicity, ototoxicity, etc. It is highly toxic and will cause great damage to the body of cancer patients.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lipidosome encapsulated ruthenium polypyridine complex and application thereof
  • Lipidosome encapsulated ruthenium polypyridine complex and application thereof
  • Lipidosome encapsulated ruthenium polypyridine complex and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Embodiment 1: a liposome-encapsulated ruthenium-polypyridine complex, comprising the following parts by weight:

[0040] 4 parts of dichlorobis(2,2'-bipyridyl)ruthenium;

[0041] 2 parts of ruthenium acetate;

[0042] 100 parts of liposome;

[0043] Blending agent 5 parts;

[0044] Antioxidant 2 parts;

[0045] 3 parts of buffer;

[0046] 2 parts of antibacterial agent;

[0047] 1 part of stabilizer;

[0048] The blending agent includes the following materials in parts by weight:

[0049] 3 parts of bis(triethanolamine) diisopropyl titanate;

[0050] 2 parts of trimethoxy[2-(7-oxabicyclo[4.1.0]hept-3-yl)ethyl]silane;

[0051] 2 parts of (3S,6E,10S)-6,10-dimethyl-3-isopropylcyclodecan-6-ene-1,4-dione;

[0052] Diethylene glycol ether 4 parts.

[0053] The liposomes include the following parts by weight:

[0054] 85 parts of lecithin;

[0055] Cholesterol 5 parts;

[0056] 8 parts of distearoylphosphatidylethanolamine-polyethylene glycol;

[0057] Polyethyle...

Embodiment 2

[0067] Embodiment 2: a liposome-encapsulated ruthenium polypyridine complex, comprising the following parts by weight:

[0068] 4 parts of dichlorobis(2,2'-bipyridyl)ruthenium;

[0069] 2 parts of ruthenium acetate;

[0070] 100 parts of liposome;

[0071] Blending agent 5 parts;

[0072] Antioxidant 2 parts;

[0073] 3 parts of buffer;

[0074] 2 parts of antibacterial agent;

[0075] 1 part of stabilizer;

[0076] The blending agent includes the following materials in parts by weight:

[0077] 3 parts of bis(triethanolamine) diisopropyl titanate;

[0078] 2 parts of trimethoxy[2-(7-oxabicyclo[4.1.0]hept-3-yl)ethyl]silane;

[0079] 2 parts of (3S,6E,10S)-6,10-dimethyl-3-isopropylcyclodecan-6-ene-1,4-dione;

[0080] Diethylene glycol ethyl ether 4 parts.

[0081] The liposomes include the following parts by weight:

[0082] Lecithin 85 parts;

[0083] Cholesterol 5 parts;

[0084] 8 parts of distearoylphosphatidylethanolamine-polyethylene glycol;

[0085] Polyeth...

Embodiment 3

[0097] Embodiment 3: a liposome-encapsulated ruthenium-polypyridine complex, comprising the following parts by weight:

[0098] 4 parts of dichlorobis(2,2'-bipyridyl)ruthenium;

[0099] 2 parts of ruthenium acetate;

[0100] 100 parts of liposome;

[0101] Blending agent 5 parts;

[0102] Antioxidant 2 parts;

[0103] 3 parts of buffer;

[0104] 2 parts of antibacterial agent;

[0105] 1 part of stabilizer;

[0106] The blending agent includes the following materials in parts by weight:

[0107] 3 parts of bis(triethanolamine) diisopropyl titanate;

[0108] 2 parts of trimethoxy[2-(7-oxabicyclo[4.1.0]hept-3-yl)ethyl]silane;

[0109] 2 parts of (3S,6E,10S)-6,10-dimethyl-3-isopropylcyclodecan-6-ene-1,4-dione;

[0110] Diethylene glycol ethyl ether 4 parts.

[0111] The liposomes include the following parts by weight:

[0112] Lecithin 85 parts;

[0113] Cholesterol 5 parts;

[0114] 8 parts of distearoylphosphatidylethanolamine-polyethylene glycol;

[0115] Polyeth...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses lipidosome encapsulated ruthenium polypyridine complex and an application thereof. Dichlorobis(2,2'-bipyridine) ruthenium and ruthenium acetate are taken as anticancer metal complex, and compared with cis-platinum, the ruthenium complex has low toxic and side effects, is easily absorbed and excreted rapidly and can suppress tumor growth and metastasis; meanwhile, the ruthenium complex is encapsulated with lipidosome, a blender, an antioxidant, a buffer agent, an antibacterial agent and a stabilizer are added, the blender adopts a mixture of titanium bis(triethanolamine)diisopropoxide, triethoxy[2-(7-oxabicyclo[4.1.0]hept-3-yl)ethyl]silane, (3S,6E,10S)-6,10-dimethyl-3-propan-2-ylcyclodec-6-ene-1,4-dione and diethylene glycol monoethyl ether, and under the joint action of the substances, intercoordination of lipidosome and the ruthenium complex can be greatly improved, and the finally prepared lipidosome encapsulated ruthenium polypyridine complex has good biocompatibility and low toxicity; furthermore, the lipidosome encapsulated ruthenium polypyridine complex can cause more serious DNA damage and can serve as a chemotherapeutic drug or a photographic developer in cancer therapy.

Description

technical field [0001] The invention relates to a ruthenium complex, in particular to a liposome-encapsulated ruthenium polypyridine complex and its application. Background technique [0002] Cancer, also known as malignant tumor, is a disease caused by the loss of normal regulation and excessive proliferation of body cells. At present, cancer has become one of the major malignant diseases threatening human death in the world; according to statistics, one of the 4-5 people who die in the United States every year is due to cancer. Cancer patients are now generally treated with a combination of surgery, chemotherapy and radiotherapy. [0003] Metal-based anticancer drugs can prevent cancer cell division and trigger cancer cell apoptosis by inducing DNA damage and disrupting the DNA repair process. Among them, the most widely used metal-based chemotherapy drug is cisplatin, which was approved by the FDA in 1978. It is one of the most widely used and most effective chemotherap...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/127A61K47/18A61K47/24A61K47/08A61K47/10A61K47/14A61K47/22A61K31/444A61K31/19A61P35/00A61P35/04A61K49/00
CPCA61K9/1271A61K31/444A61K33/24A61K47/08A61K47/10A61K47/14A61K47/18A61K47/22A61K47/24A61K49/0019A61P35/00A61P35/04A61K2300/00
Inventor 钱宇娜沈建良
Owner WENZHOU INST OF BIOMATERIALS & ENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap